Global Vaccine Contract Manufacturing Market to Reach $7 Billion by 2030
The global market for Vaccine Contract Manufacturing estimated at US$4.2 Billion in the year 2023, is expected to reach US$7 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2023-2030. Attenuated Vaccine Contract Manufacturing, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Inactivated Vaccine Contract Manufacturing segment is estimated at 7% CAGR for the next 7-year period.
The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 11.5% CAGR
The Vaccine Contract Manufacturing market in the U.S. is estimated at US$1.1 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 11.5% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.3% and 6.6% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1 Billion by the year 2030.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook